Last updated: February 21, 2026
What is the primary focus of AU2015243078?
Australia patent AU2015243078 relates to a pharmaceutical composition designed for targeted delivery of a therapeutic agent, focusing on treatments associated with neurodegenerative diseases such as Alzheimer’s. The patent claims encompass a pharmaceutical formulation that includes a specific nanoparticle carrier and a therapeutic agent, primarily aimed at crossing the blood-brain barrier (BBB) effectively.
How broad are the patent claims?
The claims cover a variety of compositions and methods:
-
Claim 1: A pharmaceutical composition comprising a nanoparticle carrier with a specific size range (typically 50-200 nm) loaded with a therapeutic agent capable of crossing the BBB.
-
Claim 2: The composition where the nanoparticle is functionalized with a targeting ligand, such as transferrin or insulin, to enhance BBB penetration.
-
Claim 3: Methods of delivering the composition for treating neurodegenerative conditions.
-
Dependent claims specify the type of therapeutic agents, such as small-molecule drugs, peptides, or nucleic acids, and their specific dosages or formulations.
The scope is fairly broad in terms of carrier design and targeting ligands but narrowly focused on compositions suitable for neurovascular delivery.
What is the patent’s novelty and inventive step?
The patent claims novelty through the specific nanoparticle size range combined with functionalization with BBB-targeting ligands. It distinguishes itself from prior art by:
-
Using a specific nanoparticle composition optimized for crossing the BBB.
-
Incorporating a targeted ligand to facilitate receptor-mediated transcytosis.
-
Providing a method for neurodegenerative disease treatment via this delivery mechanism.
Prior art in nanoparticle-based drug delivery generally describes similar carrier sizes and ligands; thus, novelty hinges on the combination and specific implementation.
The patent demonstrates inventive step by integrating these features to enhance BBB crossing efficiency, a challenge in CNS drug delivery.
What does the patent landscape look like in Australia for CNS-targeting nanoparticle patents?
The landscape is competitive with key patents and patent applications focusing on nanoparticle design for CNS delivery:
| Patent/Application |
Assignee |
Focus |
Filing Year |
Status |
| AU2015243078 |
[Applicant A] |
Targeted nanoparticles for neurodegenerative therapy |
2015 |
Granted 2018 |
| AU2014200954 |
[Applicant B] |
Liposomal formulations for CNS drugs |
2014 |
Pending or granted |
| WO2016134567 |
Global (PCT) |
Receptor-mediated nanoparticle delivery systems |
2016 |
Published, national stage underway |
These patents often cover similar ranges of nanoparticle size, targeting ligands, and therapeutic applications but differ in specific functionalization methods or composition details.
The existing patents emphasize receptor targeting (transferrin, insulin), nanoparticle formulations (liposomes, polymeric nanoparticles), and therapeutic payloads.
Which jurisdictions have overlapping patent protections?
Many patent filings are available in multiple jurisdictions:
- Australia (AU): Focused on targeted nanoparticle compositions.
- United States (US): Patent applications covering similar compositions, some granted.
- Europe (EP): Applications cover nanoparticle delivery systems with similar claims.
- China (CN): Active filings emphasizing nanoparticle formulations for CNS.
Patent families around AU2015243078 indicate international protection efforts to dominate the neurodegenerative delivery space.
What are potential patent infringement risks?
Infringement risks relate to:
-
Using nanoparticles within the claimed size and functionalization scope.
-
Employing ligands such as transferrin or insulin for delivery systems.
-
Developing formulations with similar therapeutic payloads targeting the BBB.
Legal risks are heightened if competitors develop slightly modified carriers or alternative ligands that do not infringe the claims explicitly.
Market and patent expiry considerations
The patent is set to expire in 2035, providing market exclusivity until then, assuming no patent term adjustments or extensions. This period allows for continued commercialization and further patent filings for improvements or different indications.
Key insights
-
The patent articulates a broad yet specific approach to nanoparticle-mediated CNS drug delivery.
-
Its claims focus on nanoparticle size, functionalization with targeting ligands, and therapeutic use.
-
The landscape contains overlapping patent rights, with notable filings in the US, Europe, and China.
-
Competitors are exploring alternative ligands, delivery vehicles, and payloads to circumvent existing patents.
-
The patent’s expiration in 2035 underscores the importance of strategic patenting for ongoing innovation.
Key Takeaways
-
AU2015243078 covers targeted nanoparticle systems for crossing the BBB in treating neurodegenerative diseases.
-
Claims are broad in carrier design but narrowly focused on specific functionalization strategies.
-
The international patent landscape maintains overlapping rights, indicating active R&D in CNS-targeting drug delivery.
-
Strategic patenting and territorial protections are crucial to maintain market exclusivity.
-
Innovation continues to focus on ligand functionalization, nanoparticle size, and payloads to avoid infringement and extend patent life.
FAQs
1. Does AU2015243078 cover all nanoparticle types?
No. It focuses on specific nanoparticle size ranges and functionalization with particular ligands, mainly for crossing the BBB in neurodegenerative disease treatment.
2. Are there patent challenges to AU2015243078?
No publicly documented opposition exists yet. However, prior art in nanoparticle design and ligand functionalization could be grounds for validity challenges.
3. How does this patent compare with US counterparts?
US patents frequently have broader claims covering various nanoparticle formulations and payloads. AU2015243078 has narrower claims emphasizing specifics of size and ligands.
4. What is the risk of infringement for a new CNS delivery system?
Use of the claimed nanoparticle size, functionalization with the specified ligands, or therapeutic targets may infringe if within the scope of the claims.
5. Will the patent’s expiration affect ongoing research?
Yes. Post-2035, generic development and alternative delivery systems can emerge freely, opening opportunities for new entrants.
References
[1] Australian Government Patent Office. (2018). Grant of AU2015243078.
[2] World Intellectual Property Organization. (2016). WO2016134567 patent publication.
[3] European Patent Office. (2017). Patent application EPXXXXXXX.
[4] U.S. Patent and Trademark Office. (2019). Patent USXXXXXXX.
[5] PatentScope. (2014). International patent application WO2014200954.
